Get the Stockscreener App
2.07
1.43%
-0.03
Equillium Inc stock is traded at $2.07, with a volume of 115.97K.
It is down -1.43% in the last 24 hours and up +5.08% over the past month.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
See More
Previous Close:
$2.10
Open:
$2.13
24h Volume:
115.97K
Relative Volume:
0.24
Market Cap:
$130.88M
Revenue:
$4.39M
Net Income/Loss:
$-22.40M
P/E Ratio:
-4.0604
EPS:
-0.5098
Net Cash Flow:
$-22.79M
1W Performance:
+0.98%
1M Performance:
+5.08%
6M Performance:
+64.29%
1Y Performance:
+417.24%
1-Day Range:
$2.03
$2.1601
1-Week Range:
$1.97
$2.20
52-Week Range:
$0.27
$2.70
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
2.07 | 130.88M | 4.39M | -22.40M | -22.79M | -0.5098 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-26 | Initiated | Oppenheimer | Outperform |
| Apr-16-26 | Initiated | B. Riley Securities | Buy |
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Apr-07-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
Should you add Equillium (EQ) to your watchlist today? (Bearish Momentum) 2026-05-05Overbought Alert - Newser
Equillium, Inc. Grants Inducement Stock Options to New Employees Under 2024 Inducement Plan - Quiver Quantitative
Two new Equillium hires receive options for 800,000 shares - Stock Titan
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Weekly Voice
EQ Stock Price, Quote & Chart | EQUILLIUM INC (NASDAQ:EQ) - ChartMill
B Riley Securities initiates coverage of Equillium (EQ) with buy recommendation - MSN
Equillium (EQ) price target increased by 120.00% to 5.61 - MSN
Oppenheimer Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $7 - Moomoo
Equillium (NASDAQ:EQ) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Oppenheimer Initiates Coverage on Equillium With Outperform Rating, $7 Price Target - marketscreener.com
Oppenheimer initiates Equillium stock with Outperform on UC drug By Investing.com - Investing.com Australia
Oppenheimer initiates Equillium stock with Outperform on UC drug - Investing.com
Equillium initiated with an Outperform at Oppenheimer - TipRanks
Is It Stable or Volatile | Equillium Inc. Posts 35.3% EPS Beat, Narrower Net Loss Vs EstimatesElite Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai
Roth MKM Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event - The Manila Times
EQ Reiterated by Roth Capital -- Price Target Maintained at $12 - GuruFocus
Equillium (EQ) price target increased by 10.71% to 7.90 - MSN
Roth Mkm Reiterates Buy Rating for Equillium (NASDAQ:EQ) - MarketBeat
[EFFECT] Equillium, Inc. SEC Filing - Stock Titan
Here’s what Roth Capital thinks of Equillium (EQ) stock - MSN
EQ Upgraded by B. Riley Securities -- Price Target Announced at $6.00 - GuruFocus
B. Riley Securities Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $6 - Moomoo
Equillium (NASDAQ:EQ) Earns Buy Rating from Analysts at B. Riley Financial - MarketBeat
B. Riley Initiates Equillium at Buy With $6 Price Target - marketscreener.com
B.Riley initiates Equillium stock coverage with buy rating on UC drug By Investing.com - Investing.com South Africa
B.Riley initiates Equillium stock coverage with buy rating on UC drug - Investing.com
CapEx per share of Equillium, Inc. – FWB:0FY - TradingView
Equillium Inc : B. Riley Initiates Coverage W - Moomoo
Short Interest in Equillium, Inc. (NASDAQ:EQ) Grows By 36.6% - MarketBeat
[ARS] Equillium, Inc. SEC Filing - Stock Titan
Reverse split and share increase up for Equillium (NASDAQ: EQ) stockholder vote - Stock Titan
Equillium | DEF 14A: Definitive information statements - Moomoo
Equillium (EQ) price target increased by 27.27% to 7.14 - MSN
Raymond James Initiates Coverage of Equillium (EQ) with Strong Buy Recommendation - MSN
EQ Initiates Coverage On by Raymond James -- Strong Buy Rating A - GuruFocus
Raymond James Initiates Equillium at Strong Buy With $6 Price Target - Moomoo
EQ Initiates Coverage On by Raymond James -- Strong Buy Rating Announced - GuruFocus
Raymond James initiates Equillium stock coverage with strong buy By Investing.com - Investing.com Australia
Raymond James initiates Equillium stock coverage with strong buy - Investing.com
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):